Resources Management Corp CT ADV grew its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 59.6% during the fourth quarter, Holdings Channel reports. The firm owned 84,406 shares of the company’s stock after purchasing an additional 31,505 shares during the period. AbbVie accounts for about 2.5% of Resources Management Corp CT ADV’s portfolio, making the stock its 8th largest position. Resources Management Corp CT ADV’s holdings in AbbVie were worth $19,286,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. South Plains Financial Inc. raised its holdings in shares of AbbVie by 4.1% during the 4th quarter. South Plains Financial Inc. now owns 6,474 shares of the company’s stock valued at $1,479,000 after purchasing an additional 257 shares in the last quarter. Sargent Investment Group LLC raised its holdings in shares of AbbVie by 1.1% during the 4th quarter. Sargent Investment Group LLC now owns 44,085 shares of the company’s stock valued at $10,073,000 after purchasing an additional 476 shares in the last quarter. MLP3 LLC bought a new position in shares of AbbVie during the 4th quarter valued at $591,000. MML Investors Services LLC raised its holdings in shares of AbbVie by 4.5% during the 4th quarter. MML Investors Services LLC now owns 659,523 shares of the company’s stock valued at $150,694,000 after purchasing an additional 28,130 shares in the last quarter. Finally, Mariner LLC raised its holdings in shares of AbbVie by 2.3% during the 4th quarter. Mariner LLC now owns 1,370,393 shares of the company’s stock valued at $313,145,000 after purchasing an additional 30,704 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Trending Headlines about AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
- Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
- Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
- Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means
AbbVie Trading Down 0.1%
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the business posted $2.46 EPS. AbbVie’s revenue was up 12.4% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the stock. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a report on Thursday, April 30th. Morgan Stanley raised their price target on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Guggenheim restated a “buy” rating and set a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Finally, Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.43.
Get Our Latest Research Report on AbbVie
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories
- Five stocks we like better than AbbVie
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
